


INTERNATIONAL WORKSHOP ON MONOCLONAL ANTIBODIES

FOR TREATMENT & PREVENTION OF
INFECTIOUS DISEASES | 2023

HYBRID | 18 APRIL 2023 | COPENHAGEN, DENMARK



Welcome

The **2nd International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases** is being held on the 18 April 2023 in Copenhagen, Denmark.

With more than 100 monoclonal antibodies (mAbs) in use, harnessing this technology has advanced therapeutic development for COVID-19 and underscored their utility and versatility to respond rapidly to emerging global health threats.

Recent approvals and recommendations for mAbs in preventing and treating RSV and Ebola offer novel tools to control these (re) emerging viruses.

They also offer new avenues for preventing bacterial and parasitic infections, such as *Clostridium difficile* and *Plasmodium falciparum* (causative agent of malaria tropica in humans).

Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, challenges for equitable access, and recent clinical data.

In contrast to existing programs, this workshop provides a platform for cross-disciplinary discussion, catalyzing knowledge transfer and prompting the discussions on remaining unknowns to ultimately move the field forward.

Support

To organize this much-needed interactive platform, we rely on funding. Supporting this workshop provides you the opportunity to profile your organization within the respective community and show your commitment to advancing this field.

Program Directors



Charles Flexner, MD

Johns Hopkins University School of Medicine, United States



Daniel Kuritzkes, MD

Brigham and Women's Hospital; Harvard Medical School, United States

Target Audience

- Infectious disease doctors;
- Researchers: microbiologists, virologists, immunologists;
- Pharmacologists & Pharmacists;
- Nurses;
- Healthcare Administrators;
- Policymakers, and (Non)government representatives.

Meeting Objectives

- Provide a platform to summarize key data on the clinical utility of monoclonal antibodies for the prevention and treatment of infectious disease.
- Strengthen education on the monoclonal antibody-based therapeutics for infectious diseases among healthcare professionals, researchers, and policymakers.
- Stimulate cross-disciplinary discussion on the clinical relevance of monoclonal antibody-based therapeutics in the context of public health emergencies and rethinking the approaches for conditions that are currently challenging to treat or prevent.

2021 Facts and Figures



100 Attendees

36% Specialized in Infectiology

28 Countries

6 EACCME Credits



15 Lectures

Meeting materials of the last edition can be found [here](#)

100% (strongly) agreed the lectures given in this program have increased their knowledge of HIV treatment

100% scored (very) good on overall event experience

100% (strongly) agreed the content was presented clearly